Observational · 2026
What people with hard-to-treat depression hope for when joining psychedelic trials
- Original title
- Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.
- Authors
- Poppe C, Lyck L, Bechtold L, et al.
- Journal
- Brain and behavior, 2026
- Molecules
- Psilocybin, 5-MeO-DMT
- Conditions
- Treatment-resistant depression
- Participants
- 17
- Evidence grade
- Very low
- Source
- Read the original paper
The question
What motivates people with treatment-resistant depression to join psychedelic clinical trials, and what do they expect will happen?
What they did
Researchers at a German university hospital interviewed 17 people before they were screened for two trials of 5-MeO-DMT or psilocybin for treatment-resistant depression (depression that has not responded to standard treatments). The interviews were semi-structured, meaning they followed a loose guide rather than fixed questions. Two of these people were interviewed again after they had taken part in a trial. The interview transcripts were analyzed to find recurring themes.
What they found
Two broad themes emerged: motivations and expectations, each with four sub-themes. Motivations were hope, demoralization, previous experience with psychedelics, and social reasons. Expectations covered the symptom relief people anticipated, their ideas about how the psychedelic experience would work, the importance of the setting, and how they remembered their expectations afterwards. Many described joining as a last resort after long illness and repeated treatment failures. In the two follow-up interviews, people looked back and described their initial expectations as having been stronger than they had reported at the time.
The fine print
This was a small qualitative study of 17 people at a single hospital, so the themes may not apply elsewhere. Only two people were re-interviewed after taking part, which is far too few to draw conclusions about how expectations change. The study measured no depression or treatment outcomes at all. This summary is based on the abstract only.
What it means
People entering psychedelic depression trials often arrive with strong hopes after years of failed treatment, and their memory of those hopes may shift afterwards. That matters because expectation can influence reported results, and the authors argue trials should measure and account for it.
Evidence grade: Very low. A small qualitative interview study with 17 people and no comparison group or measured clinical outcomes.
This summary is based on the study’s published abstract.